Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.32 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.32 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | GJB2 | P29033 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7802414 | 0.94 | ALDH1A1 (0.40) | CA2CA1CA9ALDH1A1TDP1 | |
| SCHEMBL5355528 | 0.84 | CA2 (0.37) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL5354914 | 0.84 | CA2 (0.37) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL13415651 | 0.83 | SMN1; SMN2 (0.42) | SMN1; SMN2ALDH1A1TDP1SSTR1SSTR2 | |
| SCHEMBL15468194 | 0.83 | SMN1; SMN2 (0.42) | SMN1; SMN2ALDH1A1TDP1SSTR1SSTR2 | |
| SCHEMBL15959279 | 0.83 | SMN1; SMN2 (0.42) | SMN1; SMN2ALDH1A1TDP1SSTR1SSTR2 | |
| SCHEMBL14387813 | 0.83 | SMN1; SMN2 (0.42) | SMN1; SMN2ALDH1A1TDP1SSTR1SSTR2 | |
| SCHEMBL18313127 | 0.81 | SMN1; SMN2 (0.38) | SMN1; SMN2CA2CA1CA9ALDH1A1 | |
| SCHEMBL19352626 | 0.81 | SMN1; SMN2 (0.38) | SMN1; SMN2CA2CA1CA9ALDH1A1 | |
| SCHEMBL13452860 | 0.80 | CA2 (0.41) | CA2CA1CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010011075-A1 | 5'-SUBSTITUTED-RIBOFURANOSYL BENZIMIDAZOLES AS ANTIVIRAL AGENTS | TOWNSEND LEROY B (US) | 2001-08-02 | — | — | US | disclosed |
| US-5874413-A | CYTOMEGALO VIRUS | UNIVERSITY OF MICHIGAN (US) | 1999-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010011075-A1 | 5'-SUBSTITUTED-RIBOFURANOSYL BENZIMIDAZOLES AS ANTIVIRAL AGENTS | ZC3HAV1, ZC3HAV1L, IFNAR1 | SMN1; SMN2 3637/4885CA2 3725/4885CA1 4050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.